Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ghielmini, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ghielmini, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S123-S126, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

The effect of Rituximab on patients with follicular and mantle-cell lymphoma

M. Ghielmini, S.-F. Hsu Schmitz, K. Bürki, G. Pichert, D. C. Betticher, R. Stupp, M. Wernli, A. Lohri, D. Schmitter, F. Bertoni and T. Cerny for the Swiss Group for Clinical Cancer Research (SAKK)

Correspondence to: M. Ghielmini, MD Istituto Oncologico della Svizzera Italiana Department of Medical Oncology Ospedale Civico 6900 Lugano, Switzerland E-mail: mghielmini{at}ticino.com

Background: Clinical activity of the anti CD-20 monoclonal antibody Rituximab has been reported in patients with follicular lymphoma (FL) and mantle-cell lymphoma (MCL).

Patients and methods: 120 patients with bi-dimensionally measurable FL or MCL (R.E.A.L. Classification) were treated with Rituximab 375 mg/m2/week for 4 weeks. A central pathology review confirmed the diagnosis of FL in 76 of 78 and of MCL in 39 of 42 cases. The response was evaluated after 8 weeks and confirmed after 12 weeks from the start of treatment.

Results: The toxicity of the treatment was, as expected, grade 1–2 fever and rigors during the first infusion and mild asthenia during the treatment period. Serious adverse events, probably or possibly related to the study treatment, included four deaths (3 of cardiac origin, 1 caused by P. carinii pneumonia) and 10 further nonfatal cases, including a permanent agranulocytosis and one case of heart failure. Response rate at week 12 was 52% for FL and 22% for MCL. After treatment, the BCL-2 rearrangement disappeared in 15 of 29 blood but only in 5 of 23 bone marrow samples; BCL-1 disappeared in 5 of 12 blood and 0 of 7 bone marrow specimens, as determined by PCR.

Conclusions: Rituximab is an active agent for the treatment of FL, while its efficacy is modest in MCL. The effect in reducing minimal residual disease is more pronounced on the blood than it is on the bone marrow.

anti CD-20 antibody, follicular lymphoma, immunotherapy, mantle-cell lymphoma, Rituximab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Leger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, et al.
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ann. Onc., October 1, 2005; 16(10): 1675 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Mangel, H. A. Leitch, J. M. Connors, R. Buckstein, K. Imrie, D. Spaner, M. Crump, N. Pennell, A. Boudreau, and N. L. Berinstein
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
Ann. Onc., February 1, 2004; 15(2): 283 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs, and N. L. Berinstein
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation
Ann. Onc., May 1, 2003; 14(5): 758 - 765.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.